Abstract
Aim: To find out statistical data regarding intravitreal injections in an outpatient department setup at a tertiary center in Oman. Design: Retrospective chart review. Methods: Data collection of patients who underwent intravitreal injections from November 2009 to May 2013 at Sultan Qaboos University Hospital. Results: Throughout a period of 42 months, a total of 711 intravitreal injections were performed. That included 214 patients (275 eyes). Around one-third of the eyes received two injections or more. The injected agents were bevacizumab (59.8%), ranibizumab (32.3%), triamcinolone (7.5%), and very few patients with endophthalmitis received intravitreal antibiotics and antifungal agents. The three most common indications for the injection therapy were diabetic macular edema (50.9%), choroidal neovascularization (24.3%), and retinal vein occlusive diseases (11.5%). Serious adverse events were rare, and they occurred as ocular (0.9% per patient) and systemic (3.3% per patient). There were 42 eyes received intravitreal triamcinolone, and 24% of them developed intraocular hypertension that required only medical treatment. Conclusion: Different intravitreal agents are currently used to treat many ocular diseases. Currently, therapy with intravitreal agents is very popular, and it carries a promising outcome with more efficiency and safety.
Original language | English |
---|---|
Pages (from-to) | 166-170 |
Number of pages | 5 |
Journal | Oman Journal of Ophthalmology |
Volume | 8 |
Issue number | 3 |
DOIs | |
Publication status | Published - Oct 1 2015 |
Keywords
- Antivascular endothelial growth factors
- choroidal neovascularization
- diabetic macular edema
- intravitreal
- Oman
- retina
- retinal vascular occlusion
ASJC Scopus subject areas
- Ophthalmology